To sum up, episodic CH is at present the only headache type other than migraine where an anti-CGRP/rec mAb, galcanezumab, has evidence-based efficacy from a RCT, although the effect size is clearly smaller than in migraine. This evidence concerns the gene CALCA and cyclic hematopoiesis.